Monoclonal Antibodies Capable of Binding SARS-CoV-2 Spike Protein Receptor Binding Motif Specifically Prevent GM-CSF Induction

Qiang, Xiaoling; Zhu, Shu; Li, Jianhua; Wang, Ping; Tracey, Kevin J.; Wang, Hai-Chao

doi:10.1101/2020.09.04.280081

Cited by 3 publications

(1 citation statement)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was further noted that the amino acid sequence similarities between SARS-CoV-2 and cellular proteins including Mitochondrial M2, F-actin and TPO were the source of reactivities. Recently, Qiang et al (2021) showed high homology between a segment (YNYLYR) in RBM and the epitope sequence NDALYEYLRQ of several monoclonal antibodies against tetranectin. The two tetranectin monoclonal antibodies were shown to bind RBM with a KD of 17.4 and 62.8 nM, respectively [57].…”

Section: Presence Of Antibodies Against S Protein In Individuals Without Sars-cov-2 Infection: Results Of Potential Molecular Mimicrymentioning

confidence: 99%

Preexisting vs. de novo antibodies against SARS-CoV-2 in individuals without or with virus infection: impact on antibody therapy, vaccine research and serological testing

Muthumani

Jeong

et al. 2021

transl med commun

View full text Add to dashboard Cite

The causative agent of the ongoing pandemic in the world is SARS-CoV-2. The research on SARS-CoV-2 has progressed with lightning speed on various fronts, including clinical research and treatment, virology, epidemiology, drug development, and vaccine research. Recent studies reported that sera from healthy individuals, who were confirmed negative for SARS-CoV-2 by RT-PCR method, tested positive for antibodies against spike and nucleocapsid proteins of SARS-CoV-2. Further, such antibodies also exhibited neutralizing activity against the virus. These observations have prompted us to prepare a commentary on this topic. While the preexisting antibodies are likely to protect against SARS-CoV-2 infection, they may also complicate serological testing results. Another unknown is the influence of preexisting antibodies on immune responses in individuals receiving vaccines against SARS-CoV-2. The commentary identifies the potential limitations with the serological tests based on spike and nucleocapsid proteins as these tests may overestimate the seroprevalence due to cross-reactive antibodies. The inclusion of tests specific to SARS-CoV-2 (such as RBD of spike protein) could overcome these limitations.

show abstract

Section: Presence Of Antibodies Against S Protein In Individuals Without Sars-cov-2 Infection: Results Of Potential Molecular Mimicrymentioning

confidence: 99%

Preexisting vs. de novo antibodies against SARS-CoV-2 in individuals without or with virus infection: impact on antibody therapy, vaccine research and serological testing

Muthumani

Jeong

et al. 2021

transl med commun

View full text Add to dashboard Cite

show abstract

Endogenous Regulation and Pharmacological Modulation of Sepsis-Induced HMGB1 Release and Action: An Updated Review

Zhu

Wang

Qiang

et al. 2021

Cells

View full text Add to dashboard Cite

Sepsis remains a common cause of death in intensive care units, accounting for approximately 20% of total deaths worldwide. Its pathogenesis is partly attributable to dysregulated inflammatory responses to bacterial endotoxins (such as lipopolysaccharide, LPS), which stimulate innate immune cells to sequentially release early cytokines (such as tumor necrosis factor (TNF) and interferons (IFNs))and late mediators (such as high-mobility group box 1, HMGB1). Despite difficulties in translating mechanistic insights into effective therapies, an improved understanding of the complex mechanisms underlying the pathogenesis of sepsis is still urgently needed. Here, we review recent progress in elucidating the intricate mechanisms underlying the regulation of HMGB1 release and action, and propose a few potential therapeutic candidates for future clinical investigations.

show abstract

Clinical Features, Diagnosis and Treatment of Covid-19

Ali

Hafeez

et al. 2020

Biol Clin Sci Res J

View full text Add to dashboard Cite

The COVID-19 has affected worldwide population at every level from advance to under developed countries and also majorly affected clinical microbiology labs. This critique covers current issues furthermore, challenges for the research facility determination of diseases brought about by extreme intense respiratory disorder coronavirus 2 (SARS-CoV-2). In the pre analytical stage, gathering the best possible respiratory diseases information at the time from the privilege has become fundamental for a brief and exact basic finding of COVID-19. Appropriate measures are required to protect lab staffs, performing the test outcomes for COVID-19. In the investigative stage, constant converse translation PCR (RT-PCR) tests remain the basic trial of decision for the etiologic determination of SARS-CoV-2 contamination while counteracting agent-based procedures are being presented as supplemental tests. In the post-analytical stage, testing results ought to be cautiously deciphered utilizing both basic and serological findings. At long last, arbitrary access, testing kits accessible for the purpose of care with versatile limits are encouraging the fast and exact finding and observing of SARS-CoV-2 contaminations and extraordinarily aid the control of this episode.

show abstract

Monoclonal Antibodies Capable of Binding SARS-CoV-2 Spike Protein Receptor Binding Motif Specifically Prevent GM-CSF Induction

Cited by 3 publications

References 45 publications

Preexisting vs. de novo antibodies against SARS-CoV-2 in individuals without or with virus infection: impact on antibody therapy, vaccine research and serological testing

Preexisting vs. de novo antibodies against SARS-CoV-2 in individuals without or with virus infection: impact on antibody therapy, vaccine research and serological testing

Endogenous Regulation and Pharmacological Modulation of Sepsis-Induced HMGB1 Release and Action: An Updated Review

Clinical Features, Diagnosis and Treatment of Covid-19

Contact Info

Product

Resources

About